Conv. Plasma
Nigella Sativa
Nitric Oxide
Peg.. Lambda

Home   COVID-19 treatment studies for Favipiravir  COVID-19 treatment studies for Favipiravir  C19 studies: Favipiravir  Favipiravir   Select treatmentSelect treatmentTreatmentsTreatments
Alkalinization Meta Lactoferrin Meta
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent:  
0 0.5 1 1.5 2+ Mortality -263% Improvement Relative Risk Oxygen therapy 41% Hospitalization time -40% Al-Muhsen et al. Favipiravir for COVID-19 LATE Is late treatment with favipiravir beneficial for COVID-19? Prospective study of 598 patients in Saudi Arabia (Jun 2020 - Jan 2021) Higher mortality (p=0.04) and lower need for oxygen therapy (p<0.0001) Al-Muhsen et al., Frontiers in Medicine, doi:10.3389/fmed.2022.826247 Favors favipiravir Favors control
Favipiravir Effectiveness and Safety in Hospitalized Moderate-Severe COVID-19 Patients: Observational Prospective Multicenter Investigation in Saudi Arabia
Al-Muhsen et al., Frontiers in Medicine, doi:10.3389/fmed.2022.826247
Al-Muhsen et al., Favipiravir Effectiveness and Safety in Hospitalized Moderate-Severe COVID-19 Patients: Observational.., Frontiers in Medicine, doi:10.3389/fmed.2022.826247
Mar 2022   Source   PDF  
  All Studies   Meta
Prospective observational study of 598 hospitalized patients in Saudi Arabia, showing higher risk of mortality and longer hospitalization time with favipiravir.
risk of death, 263.0% higher, HR 3.63, p = 0.04, treatment 156, control 442, Cox proportional hazards.
risk of oxygen therapy, 40.6% lower, RR 0.59, p < 0.001, treatment 52 of 156 (33.3%), control 248 of 442 (56.1%), NNT 4.4.
hospitalization time, 40.0% higher, relative time 1.40, p = 0.03, treatment 156, control 442.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Al-Muhsen et al., 4 Mar 2022, prospective, Saudi Arabia, peer-reviewed, 11 authors, study period June 2020 - January 2021.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperFavipiravirAll
Abstract: ORIGINAL RESEARCH published: 04 March 2022 doi: 10.3389/fmed.2022.826247 Favipiravir Effectiveness and Safety in Hospitalized Moderate-Severe COVID-19 Patients: Observational Prospective Multicenter Investigation in Saudi Arabia Edited by: Murat Akova, Hacettepe University, Turkey Saleh Al-Muhsen 1*† , Nouf S. Al-Numair 2† , Narjes Saheb Sharif-Askari 3† , Roaa Basamh 4 , Banan Alyounes 4 , Amjad Jabaan 4 , Fatemeh Saheb Sharif-Askari 3 , Mohammed F. Alosaimi 1 , Fahad Alsohime 1 , Rabih Halwani 1,3,5* and Haya Al-Saud 4,6* 1 Reviewed by: Carmen Silvia Valente Barbas, University of São Paulo, Brazil Gökhan Metan, Hacettepe University, Turkey *Correspondence: Saleh Al-Muhsen Rabih Halwani Haya Al-Saud † These authors have contributed equally to this work Specialty section: This article was submitted to Infectious Diseases – Surveillance, Prevention and Treatment, a section of the journal Frontiers in Medicine Received: 30 November 2021 Accepted: 28 January 2022 Published: 04 March 2022 Citation: Al-Muhsen S, Al-Numair NS, Saheb Sharif-Askari N, Basamh R, Alyounes B, Jabaan A, Saheb Sharif-Askari F, Alosaimi MF, Alsohime F, Halwani R and Al-Saud H (2022) Favipiravir Effectiveness and Safety in Hospitalized Moderate-Severe COVID-19 Patients: Observational Prospective Multicenter Investigation in Saudi Arabia. Front. Med. 9:826247. doi: 10.3389/fmed.2022.826247 Frontiers in Medicine | Immunology Research Laboratory, Department of Pediatrics, College of Medicine and King Saud University Medical City, King Saud University, Riyadh, Saudi Arabia, 2 The Saudi Ministry of Health and Center of Genomic Medicine, King Faisal Specialist Hospital and Research Center, Riyadh, Saudi Arabia, 3 Sharjah Institute of Medical Research, University of Sharjah, Sharjah, United Arab Emirates, 4 King Abdulaziz City for Science and Technology, Riyadh, Saudi Arabia, 5 Department of Clinical Sciences, College of Medicine, University of Sharjah, Sharjah, United Arab Emirates, 6 Hevolution Foundation, Riyadh, Saudi Arabia Objectives: There are limited data on the efficacy and safety of favipiravir antiviral in coronavirus disease 2019 (COVID-19), particularly in the more progressed disease phase. This study aims to evaluate the favipiravir effect on reducing the length of hospital stay and in-hospital mortality among moderate and severe hospitalized COVID-19 patients. Methods: A prospective, multicenter observational study was conducted that included moderate and severe hospitalized adult COVID-19 patients in four major regions (Riyadh (Riyadh), Eastern (Dammam), Al-Qassem (Buraydah), and Macca (Jeddah) of Saudi Arabia. For the primary outcome of all-cause mortality, a Cox proportional hazard analysis was performed. While the association between favipiravir use and length of hospital stay was determined using adjusted generalized linear model. This study was approved by the Central Institutional Review Board in The Saudi Ministry of Health (MoH) with the approval number IRB # 20-85-M. Results: This study included 598 moderate and severe COVID-19 patients, of whom 156 (26%) received favipiravir. Favipiravir treatment was associated with more extended hospital stays (14 vs. 10 median days, P = 0.034) and higher mortality rate (aHR 3.63; 95% CI 1.06–12.45) compared to no favipiravir regimen. Despite lack of effectiveness, favipiravir use was only associated with higher diarrhea..
Late treatment
is less effective
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop